Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Gilead's Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
04:30pm, Thursday, 20'th Feb 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the trea
GILD or VRTX: Which Is the Better Value Stock Right Now?
12:45pm, Thursday, 20'th Feb 2025
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX). But which of these two compani
Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?
10:40am, Thursday, 20'th Feb 2025
Here is how Gilead Sciences (GILD) and Natera (NTRA) have performed compared to their sector so far this year.
Gilead Sciences to Present at Upcoming Investor Conferences
04:05pm, Wednesday, 19'th Feb 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: TD Cowen Annual Health Ca
Calls of the Day: Gilead Sciences and Merck
12:59pm, Tuesday, 18'th Feb 2025
The Investment Committee debate the Calls of the Day in two biotech names.
U.S. FDA Accepts Gilead's New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review
08:30am, Tuesday, 18'th Feb 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for
Gilead Stock Rises 8% Post Q4 Earnings: Should You Buy or Sell?
02:41pm, Monday, 17'th Feb 2025
GILD's strong HIV portfolio should maintain momentum for the company. The guidance for 2025 is impressive.
Gilead Sciences, Inc. (GILD) Hit a 52 Week High, Can the Run Continue?
10:16am, Monday, 17'th Feb 2025
Gilead (GILD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Gilead Sciences (GILD) is a Top-Ranked Momentum Stock: Should You Buy?
10:56am, Thursday, 13'th Feb 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention
03:22pm, Wednesday, 12'th Feb 2025
Tuesday, Gilead Sciences Inc GILD reported fourth-quarter 2024 adjusted EPS of $1.90, beating the consensus of $1.70.
Why Gilead Sciences Stock Is Jumping Today
12:21pm, Wednesday, 12'th Feb 2025
Shares of Gilead Sciences (GILD 7.14%) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the big biotech company announced its 2024 fourth-quarter and full-year financial r
Gilead Sciences (GILD) is a Top-Ranked Value Stock: Should You Buy?
10:46am, Wednesday, 12'th Feb 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
GILD Stock Up on Q4 Earnings and Sales Beat & Upbeat '25 Guidance
09:31am, Wednesday, 12'th Feb 2025
Gilead Sciences' Q4 earnings and sales beat estimates on higher HIV, oncology and liver disease drug sales. The stock is trading up.
Pharma Stock Surges on Beat-and-Raise
09:06am, Wednesday, 12'th Feb 2025
Shares of Gilead Sciences Inc (NASDAQ:GILD) are up 4% in premarket trading, after the company delivered a strong fourth-quarter earnings beat.
Gilead Sciences: Strong Q4 Results And Huge Progress In HIV
08:25am, Wednesday, 12'th Feb 2025
Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results, a robust HIV franchise, and an imminent lenacapavir commercialization by summer 2025. Lenacapavir PrEP regimen, with 100% effective
